Antiretroviral treatment in pregnancy

Current Opinion in HIV and AIDS

Volumn 3, Issue 2, 2008, Pages 155-160

  Stek, Alice Marie ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LAC USC MEDICAL CENTER   (United States)

Author keywords

Antiretroviral medications; HIV; Pregnancy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACIDOSIS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; AREA UNDER THE CURVE; BLOOD TOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; MOTHER CHILD RELATION; NEUTROPENIA; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VIRUS TRANSMISSION;

EID: 40149093414     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282f50bfe     Document Type: Review

References (34)

1. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2 November 2007. http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf. [Accessed 16 November 2007].
2. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Supplement: Safety and toxicity of individual antiretroviral agents in pregnancy. 2 November 2007. http://aidsinfo.nih.gov/contentfiles/ PerinatalGLSafetyTox_Sup.pdf. [Accessed 16 November 2007].
3. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for1 January 1989 through 31 January 2007. http://www.apregistry.com./forms/interim_report.pdf. [Accessed 16 November 2007].
4. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV infected women. J Acquir Immune Defic Syndr 2003; 32:380-387.
5. Thorne C, Patel D, Newell ML. European Collaborative Study. Increased risk of adverse pregnancy outcomes in HIV infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18:2337-2339.
6. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV infected women in the United Kingdom and Ireland. AIDS 2007; 21:1019-1026. In this national population surveillance of 4445 pregnancies in the UK and Ireland, an increased risk of prematurity was found in pregnant women taking HAART, whether or not this included a protease inhibitor.
7. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346:1863-1870.
8. Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. Journal Acquired Immune Deficiency Syndrome 2005; 38:449-473.
9. Cotter AM, Gonzalez Garcia A, Duthely L, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193:1195-1201. This descriptive cohort study of 999 pregnant women using antiretrovirals during pregnancy and giving birth at a single site in the US from 1990 through 2002 found an increased rate of preterm delivery in women on combination antiretroviral regimens including a protease inhibitor.
10. Tuomala RE, Yawetz S. Protease inhibitor use during pregnancy: is there an obstetrical risk? J Infect Dis 2006; 193:1191-1194. This editorial commentary discusses the findings reported by Cotter et al. and other similar studies in the past and emphasizes the major benefits to maternal and infant health when treating pregnant women with antiretrovirals.
11. Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretroviral therapy during pregnancy: a single center cohort study. J Infect Dis 2007; 196:558-561. In this descriptive cohort study of 211 deliveries at one site in the UK, an increased risk for preterm delivery was found if HAART was started during pregnancy.
12. Schulte J, Dominguez K, Sukalac T, et al. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics 2006: 119; 4:900-906. Data compiled by the CDC's Pediatric Spectrum of Disease project demonstrated a decrease in preterm delivery and a decline in low birth weight from 1989 to 2004, while maternal antiretroviral use increased dramatically and preterm delivery and low birth weight increased in the general population in the United States.
13. Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 2006; 20:2345-2353. In this prospective cohort study of 681 in women on antiretrovirals in Latin America and the Caribbean, the incidence of preterm delivery and low birth weight was low and there was no statistically significantly increased risk of preterm delivery or low birth weight among women who took protease inhibitor-based HAART versus one or two NRTIs.
14. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21:607-615. The authors of this meta-analysis of 14 studies from Europe, US, and South America concluded that the use of antiretrovirals during pregnancy was not associated with an overall increased risk of preterm delivery.
15. Unadkat JD, Wara DW, Hughes MD, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2007; 51:783-786. PACTG 358 studied indinavir pharmacokinetics. Indinavir AUC was substantially lower in the third trimester of pregnancy than postpartum in women on indinavir without ritonavir.
16. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-1939. PACTG 1026 performed intensive lopinavir/ritonavir pharmacokinetics with 133/33mg capsules. Lopinavir exposure was lower during late pregnancy compared with the same women postpartum. Lopinavir AUC was below target in almost all pregnant women, and in few postpartum; 12-hour postdose levels were also much lower during pregnancy than postpartum.
17. Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS 2007; 21:643-647. In this research letter, the authors describe 12-h postdose lopinavir levels in 26 pregnant women on the standard dose of 133 mg/ritonavir 33mg capsules. Median lopinavir level was acceptable, but 15% of the women had subtherapeutic lopinavir levels.
18. Lyons F, Lechelt M, De Ruiter A. Steady-state lopinavir levels in the third trimester of pregnancy. AIDS 2007; 21:1053-1054. In this research letter, morning predose trough levels of lopinavir were measured in 26 third trimester pregnant women taking standard dose of lopinavir/ritonavir capsules. Median trough levels were similar to those described in nonpregnant populations.
19. Gavard L, Gil S, Peytavin G, et al. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol 2006; 195:296-301. In this placental perfusion study, cotyledons were perfused with lopinavir and ritonavir. Placental transfer was compatible with passive diffusion of the unbound fraction and resulted in adequate levels in the fetal compartment.
20. Gingelmaier A, Kurowski M, Kästner R, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006; 20:1737-1743. Brief maternal pharmacokinetic parameters and cord blood:maternal and amniotic fluid:maternal antiretroviral levels were determined in pregnant women undergoing cesarean section. Protease inhibitor concentrations were extremely variable. Nevirapine had better placental transfer than the protease inhibitors.
21. Best BM, Mirochnick M, Capparelli EV, et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006; 20:553-560. PACTG 1026 performed intensive maternal abacavir pharmacokinetics in late pregnancy and postpartum. Pregnancy did not affect overall abacavir exposure significantly. There was good placental transfer of abacavir.
22. Blanche S, Tardieu M, Benhammou V. Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS 2006; 20:1685-1690. In this opinion piece, Blanche and colleagues review studies of mitochondrial toxicity in infants exposed to NRTIs and defend their own work demonstrating a high incidence of mitochondrial neurological diseases in exposed children.
23. Spector S, Saitoh A. Mitochondrial dysfunction: prevention of HIV-1 mother-to-infant transmission outweighs fear. AIDS 2006; 20:1777-1778. In this editorial comment, the argument is made that serious complications due to exposure to NRTIs in utero are very rare and that the benefit of PMTCT with the use of antiretrovirals outweighs the risks.
24. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV uninfected children. AIDS 2007; 21:929-938. PACTG 219/219c evaluated >1300 HIV-uninfected children for clinical evidence of mitochondrial dysfunction. They found high rates of possible mitochondrial dysfunction, but no association with overall in-utero NRTI exposure.
25. Alimenti A, Forbes JC, Oberlander TF, et al. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. Pediatrics 2006; 118:1139-1145. In this small study of neurodevelopment among HIV-negative children with and without in-utero exposure to HAART, no difference was found when substance use during pregnancy was controlled for.
26. Gray G, Violari A, McIntyre J, et al. Antiviral activity of nucleoside analogues during short course monotherapy or dual therapy: its role in preventing HIV infection in infants. J Acquir Immune Defic Syndr 2006; 42:169-176. In this South African study comparing stavudine, didanosine, stavudine plus didanosine, and zidovudine regimens for PMTCT from 34 weeks' gestation, all four regimens appeared safe and effective.
27. Feiterna-Sperling C, Weizsaecker K, Bührer C, et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1 exposed uninfected newborn infants. J Acquir Immune Defic Syndr 2007; 45:43-50. This prospective observational study in Germany evaluated infant anemia and neutropenia after in-utero neonatal exposure to zidovudine alone versus HAART.
28. El Beitune P, Duarte G. Antiretroviral agents during pregnancy: consequences on hematologic parameters in HIV-exposed, uninfected newborn infants. Eur J Obstet Gynecol Reprod Biol 2006; 128:59-63. This small Brazilian study found more hematologic abnormalities among infants exposed to HAART versus zidovudine or no antiretrovirals.
29. Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV uninfected children: an analysis of the Women and Infants Transmission Study. J Infect Dis 2006; 194:1089-1097. This report from the large US WITS cohort evaluated various hematologic parameters in antiretroviral-exposed and unexposed HIV-negative children. Small but statistically significant differences were found.
30. European collaborative study. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clinical Infectious Diseases 2007; 44:16 47-56. This paper evaluates the time needed to achieve viral suppression with protease inhibitor-based versus nevirapine-based HAART.
31. Tang JH, Sheffield JS, Grimes J, et al. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet Gynecol 2006; 107:1115-1119. The authors report that neither protease inhibitor exposure, nor HIV infection had an effect on screening results for diabetes.
32. Hitti J, Anderson J, McComsey G, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 2007; 196:331e1-331e7. ACTG 5084, an observational cohort study, evaluated glucose tolerance during pregnancy, according to antiretroviral regimen and found a high rate of glucose intolerance, but no association with protease inhibitors.
33. Livingston EG, Cohn SE, Yang Y, et al. Lipids and lactate in human immunodeficiency virus-1-infected pregnancies with or without protease inhibitor-based therapy. Obstet Gynecol 2007; 110:391-397. ACTG 5084 also evaluated lipid and lactate levels and gastrointestinal symptoms in pregnant women on protease inhibitor regimens. Overall, findings were reassuring.
34. Kourtis AP, Bansil P, McPheeters M, et al. Hospitalizations of pregnant HIV-infected women in the USA prior to and during the era of HAART. AIDS 2006; 20:1823-1831. A study of hospitalizations of pregnant HIV-infected women in the US prior to and during the era of HAART suggested that the antiretroviral regimens currently being used to treat HIV-infected women during pregnancy are not associated with major adverse pregnancy outcomes.